Ilika Plc (LON:IKA) CEO Graeme Purdy says the company has reached a key commercial inflection point, with Stereax now shipping into medical device supply chains and revenues expected to multiply in the current financial year. He also explains how Goliath remains aligned with EV demand through grant-backed development, while new opportunities in e-bikes and defence applications could broaden the battery platform’s relevance beyond automotive.
Key Moments
00:13 — Trading update highlights Stereax’s commercial transition
00:36 — Product-related Stereax revenues now recognised
01:11 — Commercial-grade electrodes shipped to Cirtec Medical
01:27 — Royalties expected as end products reach customers
01:39 — Stereax applications across orthodontics and diagnostics
02:06 — Smart orthopaedics and implanted sensor opportunities
02:36 — Neurostimulation and ophthalmic use cases
03:21 — Goliath revenue support through DRIVE35 grants
03:50 — Jaguar Land Rover and Oxford steer the roadmap
04:24 — Further grant opportunities through DRIVE35 and Horizon Europe
04:48 — EV market reset across the US, China and Europe
06:00 — Europe posts strong EV growth momentum
07:20 — Goliath roadmap expands into new sectors
07:37 — Brompton collaboration on safer e-bikes
07:49 — UK Defence Agency testing of 10Ah cells
08:17 — Annual results due 29 July with Investor Meet Company presentation
About Ilika Plc
Ilika plc develops solid-state battery technology. Its Stereax batteries are designed for miniature medical and industrial devices, while its Goliath programme targets larger-format cells for electric vehicles and other high-performance applications.
